Quest Diagnostics (DGX) Cash from Financing Activities (2009 - 2026)

Quest Diagnostics has disclosed Cash from Financing Activities across 18 years of filings, most recently posting -$152.0 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$152.0 million, up 72.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$979.0 million (down 244.82% YoY), and the FY2025 annual result was -$1.4 billion, down 228.04% from the prior year.
• Cash from Financing Activities came in at -$152.0 million for Q1 2026 at Quest Diagnostics, up from -$287.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.8 billion in Q3 2024 to a low of -$561.0 million in Q1 2025.
• The 5-year median for Cash from Financing Activities is -$242.0 million (2022), against an average of -$119.3 million.
• Across the five-year window, Cash from Financing Activities tumbled 1147.37% in 2022 and surged 2232.53% in 2024, its largest moves.
• Quest Diagnostics' Cash from Financing Activities stood at -$545.0 million in 2022, then jumped by 123.85% to $130.0 million in 2023, then tumbled by 230.77% to -$170.0 million in 2024, then slumped by 68.82% to -$287.0 million in 2025, then jumped by 47.04% to -$152.0 million in 2026.
• The last three Cash from Financing Activities figures came in at -$152.0 million (Q1 2026), -$287.0 million (Q4 2025), and -$247.0 million (Q3 2025), per Business Quant data.